Tolebrutinib had the most protective effect against disability worsening at 6 months in patients with multiple sclerosis who ...

Dr Annalisa Morgan reflects on new data on DMTs for RRMS that highlighted the potential of BTK inhibitors such as ...

A new analysis provides substantial evidence that paramagnetic rim lesions drive disability in MS and are targetable with a ...

Sanofi has bolstered the case for its oral BTK inhibitor tolebrutinib as a treatment for multiple sclerosis (MS), due to be filed for approval in the latter half of this year, with new data in a ...

Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three ...

These benefits were reported over a mean follow-up of two years, and… Treatment with the investigational BTK inhibitor tolebrutinib significantly delayed the onset of confirmed disability ...

WEST PALM BEACH, Fla. — Tolebrutinib had the most protective effect against disability worsening at 6 months in patients with multiple sclerosis who had a greater number of MRI paramagnetic rim ...

People with multiple sclerosis (MS) who switch from a high- to a moderate-efficacy disease-modifying therapy (DMT) increase their risk of disease activity, especially younger adults and those ...